Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 12/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23888913 | 0.81 | PNMT (0.32) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL2595915 | 0.78 | PNMT (0.36) | PNMTASIC3SLC6A4ADRA2AADRA2B | |
| SCHEMBL17493533 | 0.76 | FAAH (0.39) | — | |
| SCHEMBL31757806 | 0.75 | HTR2A (0.41) | PNMTASIC3SLC6A4HTR2AHTR2C | |
| SCHEMBL4353832 | 0.72 | PNMT (0.34) | PNMTASIC3SLC6A4HTR2AHTR2C | |
| SCHEMBL19203254 | 0.69 | PNMT (0.46) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| SCHEMBL23877925 | 0.69 | FFAR1 (0.39) | — | |
| SCHEMBL15825529 | 0.69 | PNMT (0.46) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| SCHEMBL17545451 | 0.67 | ESR1 (0.31) | — | |
| SCHEMBL12184493 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177282-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3177282-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-06 | — | — | EP | disclosed |
| US-10662171-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662171-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20170217920-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-08-03 | — | — | US | disclosed |
| US-20170217920-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-08-03 | — | — | US | disclosed |
| US-20170217920-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-08-03 | — | — | US | disclosed |
| EP-3177282-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016022448-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016022448-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662171-B2 | Antidiabetic bicyclic compounds | GPR119, GPR65, GLP1R | PNMT 4478/4885ASIC3 2661/4885SLC6A4 2709/4885 |
| US-20170217920-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, GPR65, GLP1R | PNMT 4478/4885ASIC3 2661/4885SLC6A4 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.